Search Results - "EISERMANN, Mona"
-
1
Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models
Published in Clinical cancer research (15-11-2010)“…Atu027, a novel RNA interference therapeutic, has been shown to inhibit lymph node metastasis in orthotopic prostate cancer mouse models. The aim of this study…”
Get full text
Journal Article -
2
SLN124, a GalNAc‐siRNA Conjugate Targeting TMPRSS6, Efficiently Prevents Iron Overload in Hereditary Haemochromatosis Type 1
Published in HemaSphere (01-12-2019)“…Supplemental Digital Content is available in the text…”
Get full text
Journal Article -
3
Preclinical Toxicological Assessment of A Novel siRNA, SLN360, Targeting Elevated Lipoprotein (a) in Cardiovascular Disease
Published in Toxicological sciences (24-09-2022)“…Abstract SLN360 is a liver-targeted N-acetyl galactosamine (GalNAc)-conjugated small interfering RNA (siRNA) with a promising profile for addressing…”
Get full text
Journal Article -
4
Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease
Published in Atherosclerosis (01-05-2022)“…The LPA gene encodes apolipoprotein (a), a key component of Lp(a), a potent risk factor for cardiovascular disease with no specific pharmacotherapy. Here we…”
Get full text
Journal Article -
5
SLN124, a GalNac‐siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron‐overload in a mouse model of β‐thalassaemia
Published in British journal of haematology (01-07-2021)“…Summary Beta‐thalassaemia is an inherited blood disorder characterised by ineffective erythropoiesis and anaemia. Consequently, hepcidin expression is reduced…”
Get full text
Journal Article -
6
Therapeutic Small Interfering RNA Targeting Complement C3 in a Mouse Model of C3 Glomerulopathy
Published in The Journal of immunology (1950) (01-04-2022)“…Alternative pathway complement dysregulation with abnormal glomerular C3 deposits and glomerular damage is a key mechanism of pathology in C3 glomerulopathy…”
Get full text
Journal Article -
7
Abstract 14720: Pre-clinical Safety Assessment of SLN360, a Novel Short Interfering Ribonucleic Acid Targeting LPA
Published in Circulation (New York, N.Y.) (17-11-2020)“…IntroductionSLN360 is a liver-targeted N-acetyl galactosamine (GalNAc)-conjugated siRNA with a promising profile for addressing Lp(a)-related cardiovascular…”
Get full text
Journal Article -
8
SLN140 a Small Interfering RNA Targeting Protein S Improves Hemostasis Potency in Hemophilia
Published in Blood (15-11-2022)Get full text
Journal Article -
9
Targeting Protein S Using Small Interfering RNA Is Well Tolerated and Protects Mice with Hemophilia a from Acute Hemarthrosis
Published in Blood (05-11-2020)“…Introduction & Aim: Hemophilia A (HA) is an X-linked disorder caused by an absence or a reduction of coagulation factor VIII. Patients with HA often suffer…”
Get full text
Journal Article -
10
Abstract 9538: A Novel Short Interfering Ribonucleic Acid Shows Potent and Sustained Reduction of Serum Lipoprotein (a) in Cynomolgus Monkeys
Published in Circulation (New York, N.Y.) (19-11-2019)“…IntroductionSLN360 is a liver targeted GalNAc-conjugated siRNA developed for the treatment of cardiovascular disorders associated with elevated Lp(a). Lp(a) is…”
Get full text
Journal Article